Xenter, Inc. appoints Mark Turco, MD as president of the medical technologies business unit
Salt Lake City — Following the formation of the Xenter Therapeutics business unit, Xenter, Inc. (XenterMD.com), the first purpose-built medical device-data-drug technologies company, today announced the appointment of Mark Turco, MD, as President of Xenter Medical Technologies (formerly Xenter Hospital Technologies). Xenter’s Medical Technologies business unit is developing a new global platform of smart medical devices, initially focusing on vascular imaging and physiology technologies for interventional medical procedures.
Dr. Turco joins Xenter most recently from Sirtex Medical where he served as EVP of Research and Development and Global Chief Medical Officer, leading the development and delivery of interventional oncology technologies worldwide. Prior to Sirtex, Dr. Turco served as chief innovation and corporate outreach officer for the University of Pennsylvania’s Penn Center for Innovation, where he led Penn’s corporate outreach team, fostered multiple industries and academic partnerships across healthcare, engineering, and business, and established a new medical device center.
Dr. Turco began his 20-year clinical practice at Washington Adventist Hospital in Washington, DC, where he served as the Director, Center for Cardiac and Vascular Research before joining Covidien as Chief Medical Officer. Following Medtronic’s $47B acquisition of Covidien in 2015, Dr. Turco was appointed VP and chief medical officer of the Aortic, Peripheral & Vascular Divisions at Medtronic prior to joining Penn.
“I am very excited to join Xenter in this pivotal leadership role,” says Dr. Turco. “I look forward to aiding in the development of medical technologies using Xenter’s three pillars: medical devices, health data, and therapeutic drugs. I am joining a globally recognized and experienced team that has been tasked with transforming the collection of procedural and patient data using a new global platform that leverages smart wireless medical technologies. This platform seeks to provide new techniques for both therapeutic drug discovery and the improvement of medical procedures, all of which translates to better outcomes for patients. My combined experiences to date have provided me with the unique skills to lead this multi-disciplinary team of technologists, scientists, and engineers.”
“Xenter is continuing our commitment to bringing the most experienced and visionary leaders to the world’s first purpose-built medical device-data-drug company and tasking them with introducing change, developing new wireless platforms for smart medical devices, and harnessing the power of Physical Intelligence to improve patient care. As a former patient, my goal has been to work with people like Mark Turco, MD, to develop the medical technologies platform of the future and characterize the differences between AI and PI,” stated Richard J. Linder, founder, chairman, and CEO of Xenter, Inc. “Dr. Turco brings a wealth of skill and insight to Xenter and possesses the clinical knowledge and industry experience to drive the change we desire to achieve in medical devices and data.”
“We believe that medical data should be owned by patients, that ease of accessibility to medical data is of vital importance to both physicians and patients, and that new global platforms are needed for the collection and management of medical data,” continues Linder. “I’m looking forward to working with Dr. Turco as we relentlessly pursue the development of Xenter’s new wireless platform.”